Natixis Advisors LLC Acquires 5,313 Shares of argenex SE (NASDAQ:ARGX)

Key Points

• Natixis Advisors LLC increased its stake in argenex SE by 33.4% in the first quarter, acquiring an additional 5,313 shares for a total valuation of $12,569,000.
• Institutional investors own 60.32% of argenex, with significant increases in holdings from several hedge funds, including a massive 1,133.3% stake increase by Huntington National Bank.
• Analysts have generally rated argenex positively, with a consensus rating of "Buy" and a price target of $736.81, following recent upgrades from firms like Deutsche Bank and Robert W. Baird.

Natixis Advisors LLC grew its position in argenex SE (NASDAQ:ARGX - Free Report) by 33.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,236 shares of the company's stock after buying an additional 5,313 shares during the quarter. Natixis Advisors LLC's holdings in argenex were worth $12,569,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC raised its position in argenex by 17.2% during the fourth quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after acquiring an additional 824,750 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in argenex during the fourth quarter valued at approximately $91,013,000. GAMMA Investing LLC grew its holdings in argenex by 53,684.9% during the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock valued at $802,200,000 after purchasing an additional 135,286 shares during the last quarter. Marshall Wace LLP grew its holdings in argenex by 184.7% during the fourth quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after purchasing an additional 124,271 shares during the last quarter. Finally, Capital World Investors grew its holdings in argenex by 5.1% during the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after purchasing an additional 86,687 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on ARGX. Oppenheimer increased their price target on argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a report on Friday, May 9th. HC Wainwright increased their price target on argenex from $720.00 to $774.00 and gave the company a "buy" rating in a report on Friday. Deutsche Bank Aktiengesellschaft upgraded argenex from a "hold" rating to a "buy" rating in a report on Tuesday, July 8th. Citigroup restated a "buy" rating on shares of argenex in a research note on Wednesday, May 21st. Finally, Morgan Stanley raised their price objective on shares of argenex from $700.00 to $766.00 and gave the stock an "overweight" rating in a research note on Friday. Nineteen equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, argenex has an average rating of "Buy" and a consensus target price of $746.81.

argenex Price Performance

Shares of argenex stock traded down $15.42 during trading on Tuesday, hitting $674.90. 464,778 shares of the company were exchanged, compared to its average volume of 445,794. The firm has a market capitalization of $41.30 billion, a P/E ratio of 34.61, a price-to-earnings-growth ratio of 0.86 and a beta of 0.39. argenex SE has a 1-year low of $485.91 and a 1-year high of $696.21. The firm's fifty day moving average price is $575.07 and its 200 day moving average price is $597.18.

argenex (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.90. The company had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. As a group, equities research analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.